| Literature DB >> 35736990 |
Andreza R Garcia1, Yasmin P G Silva-Luiz2, Celuta S Alviano3, Daniela S Alviano3, Alane B Vermelho3, Igor A Rodrigues4.
Abstract
Leishmaniasis is a vector-borne disease against which there are no approved vaccines, and the treatment is based on highly toxic drugs. The alkaloids consist of a chemical class of natural nitrogen-containing substances with a long history of antileishmanial activity. The present study aimed at determining the antileishmanial activity and in silico pharmacokinetic and toxicological potentials of tryptanthrin alkaloid. The anti-Leishmania amazonensis and anti-L. infantum assays were performed against both promastigotes and intracellular amastigotes. Cellular viability was determined by parasites' ability to grow (promastigotes) or differentiate (amastigotes) after incubation with tryptanthrin. The mechanisms of action were explored by mitochondrion dysfunction and apoptosis-like death evaluation. For the computational pharmacokinetics and toxicological analysis (ADMET), tryptanthrin was submitted to the PreADMET webserver. The alkaloid displayed anti-promastigote activity against L. amazonensis and L. infantum (IC50 = 11 and 8.0 μM, respectively). Tryptanthrin was active against intracellular amastigotes with IC50 values of 75 and 115 μM, respectively. Mitochondrial membrane depolarization was observed in tryptanthrin-treated promastigotes. In addition, parasites undergoing apoptosis-like death were detected after 18 h of exposure. In silico ADMET predictions revealed that tryptanthrin has pharmacokinetic and toxicological properties similar to miltefosine. The results presented herein demonstrate that tryptanthrin is an interesting drug candidate against leishmaniasis.Entities:
Keywords: alkaloid; antileishmanial activity; apoptosis-like; computational analysis; tryptanthrin
Year: 2022 PMID: 35736990 PMCID: PMC9231190 DOI: 10.3390/tropicalmed7060112
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Figure 1Chemical structure of tryptanthrin.
Inhibition effects and cytotoxicity of tryptanthrin alkaloid. The results are expressed as a mean ± standard error of at least two independent experiments. Amphotericin B was used as a reference drug in the treatment of amastigote-infected macrophages.
| Drugs | MØ |
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CC50 (µM) | MLCPro (µM) | SLCPro (µM) | IC50Pro (µM) | IC50Ama (µM) | SI | MLCPro (µM) | SLCPro (µM) | IC50Pro (µM) | IC50Ama (µM) | SI | |
| Tryp | 465 ± 31.05 | 126 | 63 | 11 ± 1.06 | 75 ± 11.63 | 6.2 | 126 | 63 | 8.0 ± 2.60 | 115 ± 2.79 | 4.0 |
| Amph B | 5.0 ± 0.89 | n.d. | n.d. | 0.68 ± 0.03 | 0.37 ± 0.14 | 13.5 | n.d. | n.d. | 0.86 ± 0.36 | 1.11 ± 0.21 | 4.5 |
Tryp, tryptanthrin; Amph B, amphotericin B; MØ, RAW 264.7 macrophages; MLC, minimal leishmanicidal concentration; SLCPro, sub-leishmanicidal concentration (MLC/2); IC50Pro, 50% inhibitory concentration of the drug against promastigote forms; IC50Ama, 50% inhibitory concentration of the drug against intracellular amastigote forms; SI, selectivity index (CC50/IC50Ama). n.d., not determined.
Figure 2Effect of tryptanthrin on the mitochondrion membrane potential of Leishmania spp. Promastigote forms of L. amazonensis and L. infantum were treated with IC50 (11 and 8.0 µM, respectively) or SLC (63 µM, for both parasite species). A statistical analysis of the differences between mean values obtained for the experimental groups was done by two-way ANOVA with Sidak’s multiple comparisons test. Asterisks indicate treatment that was significantly different compared to the control, in which * p < 0.05 and ** p < 0.005. IC50, half-maximal inhibitory concentration; SLC, sub-leishmanicidal concentration (MLC/2).
Figure 3Effect of tryptanthrin on the autophagic activity of Leishmania spp. Promastigote forms of L. amazonensis and L. infantum were treated with IC50 values (11 and 8.0 µM, respectively) of tryptanthrin. The results are presented as the mean percentage relative to the control. Statistical analysis of the differences between mean values obtained for the experimental groups was done by Student’s t-test. The asterisks indicate significant differences (* p < 0.05) in the autophagic activity between treated parasites and their respective controls (100% activity).
Figure 4Representative flow cytometry dot-plots of apoptosis-like cell death of Leishmania spp. promastigotes induced by tryptanthrin. (A) Untreated L. amazonensis; (B) L. amazonensis treated with amphotericin B (IC50 = 0.68 µM); (C) L. amazonensis treated with tryptanthrin (IC50 = 11 µM); (D) Untreated L. infantum; (E) L. infantum treated with amphotericin B (IC50 = 0.86 µM); (F) L. infantum treated with tryptanthrin (IC50 = 8.0 µM).
Flow cytometry analysis of L. amazonensis and L. infantum promastigotes treated with tryptanthrin. The results are demonstrated as the percentage of propidium iodide (necrosis), annexin FITC-V (early apoptosis), and propidium iodide/annexin FITC-V (late apoptosis) positive parasites.
| Drugs |
|
| ||||||
|---|---|---|---|---|---|---|---|---|
| PI | AV | PI/AV | Total | PI | AV | PI/AV | Total | |
| Tryp | 0.79 ± 0.07 | 24.73 ± 5.94 | 1.35 ± 0.51 | 26.08 | 0.06 ± 0.02 | 22.90 ± 0.42 | 2.80 ± 0.20 | 25.70 |
| Amph B | 0.09 ± 0.04 | 15.98 ± 2.81 | 0.88 ± 0.02 | 16.86 | 0.09 ± 0.03 | 17.06 ± 7.53 | 4.81 ± 1.11 | 21.87 |
| Control | 0.23 ± 0.04 | 0.25 ± 0.13 | 2.5 ± 0.31 | 2.98 | 0.11 ± 0.02 | 1.42 ± 025 | 0.64 ± 0.32 | 2.06 |
Tryp, tryptanthrin; Amph B, amphotericin B; AV, annexin FITC-V; PI, propidium iodide.
In silico predicted pharmacokinetic and toxicological parameters of tryptanthrin and miltefosine.
| Drug | ADME | Druglikeness | Toxicity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SP a | HIA b | PPB c | MDCK d | CYP e
| CYP f
| BBB g | Rule of 5 h | Ames Test i | CarR j | CarM j | hERG k | |
| Tryp | −3.8 | 97.4 | 85.8 | 166.2 | non | CYP3A4 | 1.94 | Suitable | Mutagen | Positive | Positive | Medium risk |
| MTF | −0.80 | 98.1 | 86.2 | 43.4 | CYP2D6 | CYP3A4 | 0.13 | Suitable | Mutagen | Positive | Negative | Low risk |
Tryp, tryptanthrin; MTF, miltefosine; a In vitro skin permeability (transdermal delivery); b Human intestinal absorption data are the sum of bioavailability and absorption evaluated from ratio of excretion or cumulative excretion in urine, bile and feces; c In vitro plasma protein binding; d In vitro MDCK (Madin-Darby canine kidney) reliable cell model for the prediction of oral drug absorption; e In vitro inhibition of cytochrome P450 isoforms; f In vitro substrate of cytochrome P450 isoforms; g In vivo blood-brain barrier penetration expressed as the ratio between steady-state concentration of radiolabeled compounds in brain and peripheral blood; h Theoretical oral bioavailability based on the Lipinski’s Rule of Five (Lipinski, 2004); i Method to test mutagenicity of a compound based on its ability to cause a reversion on growth of histidine-dependent Samonella typhimurium in a histidine-free medium; j Rodent carcinogenicity two year assay of rat (CarR) and mouse (CarM) by backward elimination and Rprop neural net method; k Inhibition of the human Ether-a-go-go Related Gene (hERG) potassium channel.